The EU AI Act (Artificial Intelligence Act Regulation EU 2024/1689), which came into force on 1 August 2024, establishes a harmonised framework for regulating AI systems. It impacts the use of AI in medical settings, particularly when integrated with the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR).

In this article, we will explore how AI is reshaping the pharmaceutical landscape and examine its implications for the workforce, presenting a balanced view on the potential benefits and challenges ahead.

The convergence of artificial intelligence and pharmaceutical innovation is no longer a distant vision; it’s today’s reality. With a projected market size of $116.49 billion by the end of 2025 and a 27% compound annual growth rate (CAGR), AI in pharma is reshaping everything from drug discovery to diagnostics.

In the fast-paced world of drug discovery, artificial intelligence (AI) has become essential, transforming the way researchers identify...

The digital health landscape is evolving quickly, thanks to advances in technology like artificial intelligence (AI) and machine learning...